INOVIO (NASDAQ:INO), a biotechnology company, announced on Thursday positive results from a Phase 1b clinical trial assessing INO-4201, a DNA vaccine candidate, as an Ebola booster in healthy adult participants who earlier received a single injection of Ervebo.

INO-4201 was well- tolerated in the trial and increased humoral responses in 100% (36 of 36) of treated participants. The study assessed 46-participant in a randomised, placebo-controlled Phase 1b trial (NCT04906629) to evaluate INO-4201's safety, tolerability, and immunogenicity in healthy adult subjects who earlier received a single injection of Ervebo, a vaccine approved by the US Food and Drug Administration (FDA) for the prevention of disease caused by Zaire ebolavirus in individuals 18 years of age and older.

The trial was designed to test whether INO-4201 can be used as a booster in healthy participants previously vaccinated with Ervebo. The trial was spearheaded by Global Urgent and Advanced Research and Development (GuardRX), sponsored by Geneva University Hospitals, and funded by the US Defense Advanced Research Projects Agency (DARPA).